BMS CEO Giovanni Caforio (File photo/AP)
January 1, 2021 09:59 AM ESTUpdated 10:15 AM
Deals

A $6B CVR goes pfffft as the game clock runs out on a New Year's dead­line for Bris­tol My­er­s' liso-cel ap­pli­ca­tion

John Carroll

Editor & Founder

The last sec­onds of 2020 have ticked away, drain­ing the last of the sand in the hour glass along with any re­main­ing hopes in a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Af­ter Phase 3 de­pres­sion set­back, Neumo­ra paus­es two tri­als to make changes, scraps an­oth­er

No­vo Nordisk signs $354M part­ner­ship with AI-guid­ed biotech for ‘risky’ new meta­bol­ic mech­a­nisms

Pro­tag­o­nist, Takeda's prof­it shar­ing deal un­der spot­light af­ter Phase 3 blood dis­or­der tri­al win

AD­Cs from a decade-old Sin­ga­pore biotech find new life with $187M

Ab­b­Vie fi­nal­ly en­ters obe­si­ty race with $350M up­front for Gubra’s amylin

sponsored

The per­fect storm: Why every­thing is in place for 2025 to be the year of GxP AI

A service from the Financial Times